Sandrine Micallef

1.0k total citations · 1 hit paper
24 papers, 678 citations indexed

About

Sandrine Micallef is a scholar working on Molecular Biology, Statistics and Probability and Oncology. According to data from OpenAlex, Sandrine Micallef has authored 24 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Statistics and Probability and 5 papers in Oncology. Recurrent topics in Sandrine Micallef's work include Statistical Methods in Clinical Trials (6 papers), Carcinogens and Genotoxicity Assessment (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Sandrine Micallef is often cited by papers focused on Statistical Methods in Clinical Trials (6 papers), Carcinogens and Genotoxicity Assessment (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Sandrine Micallef collaborates with scholars based in France, Switzerland and United States. Sandrine Micallef's co-authors include Joseph G. Ibrahim, Billy Amzal, Beat Neuenschwander, Fang Chen, Scott Berry, Stacy Lindborg, Nathan Enas, Satrajit Roychoudhury, Brian P. Hobbs and Kert Viele and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Sandrine Micallef

23 papers receiving 663 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of historical control data for assessing treatment effects in clinical trials

2013 327 citations Kert Viele, Scott Berry et al. Pharmaceutical Statistics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandrine Micallef France	10	292	111	96	79	68	24	678
Alexei Dmitrienko United States	9	294 1.0×	96 0.9×	160 1.7×	184 2.3×	87 1.3×	25	852
Finlay MacKenzie United Kingdom	19	119 0.4×	21 0.2×	130 1.4×	52 0.7×	25 0.4×	40	1.2k
Jonathan Denne United States	15	401 1.4×	91 0.8×	105 1.1×	63 0.8×	56 0.8×	30	1.3k
Pamela F. Schwartz United States	15	32 0.1×	120 1.1×	102 1.1×	134 1.7×	42 0.6×	35	889
Jacqueline Corrigan‐Curay United States	9	106 0.4×	148 1.3×	135 1.4×	44 0.6×	119 1.8×	13	616
Anna McGlothlin United States	9	92 0.3×	42 0.4×	52 0.5×	49 0.6×	189 2.8×	16	504
Anja Schiel Norway	13	125 0.4×	124 1.1×	150 1.6×	89 1.1×	35 0.5×	24	582
Alberto Salván Italy	13	68 0.2×	32 0.3×	22 0.2×	80 1.0×	25 0.4×	27	532
Ellie Siden Canada	10	110 0.4×	85 0.8×	88 0.9×	64 0.8×	81 1.2×	15	527
Hongyuan Cao United States	16	101 0.3×	18 0.2×	215 2.2×	64 0.8×	104 1.5×	63	908

Countries citing papers authored by Sandrine Micallef

Since Specialization

Citations

This map shows the geographic impact of Sandrine Micallef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandrine Micallef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandrine Micallef more than expected).

Fields of papers citing papers by Sandrine Micallef

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandrine Micallef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandrine Micallef. The network helps show where Sandrine Micallef may publish in the future.

Co-authorship network of co-authors of Sandrine Micallef

This figure shows the co-authorship network connecting the top 25 collaborators of Sandrine Micallef. A scholar is included among the top collaborators of Sandrine Micallef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandrine Micallef. Sandrine Micallef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Papadopoulos, Kyriakos P., Manish Sharma, Reinhard Dummer, et al.. (2024). Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data.. Journal of Clinical Oncology. 42(16_suppl). 3120–3120. 5 indexed citations

Roth, Patrick, Kyriakos P. Papadopoulos, María Vieito, et al.. (2023). RTID-03. A PHASE 1/2 STUDY OF THE WEE1 INHIBITOR DEBIO 0123 IN COMBINATION WITH TEMOZOLOMIDE +- RADIOTHERAPY IN ADULTS WITH RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology. 25(Supplement_5). v258–v259. 1 indexed citations

Looney, Cary M., Jay Garg, Thomas H. Schindler, et al.. (2023). Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients. Transplantation Direct. 9(2). e1436–e1436. 8 indexed citations

Micallef, Sandrine, Alexandre Sostelly, Jiawen Zhu, Paul Baverel, & François Mercier. (2022). Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial. Contemporary Clinical Trials Communications. 26. 100901–100901. 7 indexed citations

Peipert, John Devin, et al.. (2022). POSC370 Health-Related Quality of Life of Naratuximab Emtasine + Rituximab (N+R) in Second Line and Heavily Pre-Treated Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): An Analysis of the Functional Assessment of Cancer Therapy Lymphoma (FACT-LYM) Measure and Mapped EQ-5D Values from a Phase II Trial. Value in Health. 25(1). S245–S245. 1 indexed citations

Papadopoulos, Kyriakos P., Manish Sharma, Reinhard Dummer, et al.. (2022). A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS2702–TPS2702. 4 indexed citations

Levy, Moshe, Marek Trněný, Wojciech Jurczak, et al.. (2021). SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY. Hematological Oncology. 39(S2). 3 indexed citations

Levy, Moshe, Deepa Jagadeesh, Marek Trněný, et al.. (2021). Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study. Blood. 138(Supplement 1). 526–526. 11 indexed citations

Colin, Pierre, Maud Delattre, Pascal Minini, & Sandrine Micallef. (2017). An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials. Journal of Biopharmaceutical Statistics. 27(6). 1054–1072. 3 indexed citations

10.

Bédard, Philippe L., Michael A. Davies, Scott Kopetz, et al.. (2017). First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer. 124(2). 315–324. 30 indexed citations

11.

Bédard, Philippe L., Michael A. Davies, Scott Kopetz, et al.. (2015). First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. Journal of Clinical Oncology. 33(15_suppl). 2564–2564. 6 indexed citations

12.

Gould, A. Lawrence, Mark E. Boye, Michael J. Crowther, et al.. (2014). Joint modeling of survival and longitudinal non‐survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group. Statistics in Medicine. 34(14). 2181–2195. 92 indexed citations

13.

Lacroix, Ludovic, Alexander Valent, Antoine E. Melkane, et al.. (2014). MET Genetic Abnormalities Unreliable for Patient Selection for Therapeutic Intervention in Oropharyngeal Squamous Cell Carcinoma. PLoS ONE. 9(1). e84319–e84319. 14 indexed citations

14.

Viele, Kert, Scott Berry, Beat Neuenschwander, et al.. (2013). Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics. 13(1). 41–54. 327 indexed citations breakdown →

15.

Beaudouin, Rémy, Sandrine Micallef, & Céline Brochot. (2010). A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan. Regulatory Toxicology and Pharmacology. 57(1). 103–116. 56 indexed citations

16.

Smith, Thomas J., Frédéric Y. Bois, Yu-Sheng Lin, et al.. (2008). Quantifying heterogeneity in exposure–risk relationships using exhaled breath biomarkers for 1,3-butadiene exposures. Journal of Breath Research. 2(3). 37018–37018. 2 indexed citations

17.

Micallef, Sandrine, Billy Amzal, Véronique Bach, et al.. (2007). Sequential Updating of a New Dynamic Pharmacokinetic Model for Caffeine in Premature Neonates. Clinical Pharmacokinetics. 46(1). 59–74. 6 indexed citations

18.

Chardon, Karen, Pierre Tourneux, Sandrine Micallef, et al.. (2007). Ventilatory Response to a Hyperoxic Test Is Related to the Frequency of Short Apneic Episodes in Late Preterm Neonates. Pediatric Research. 62(5). 591–596. 38 indexed citations

19.

Chiu, Weihsueh A., Sandrine Micallef, A. C. Monster, & Frédéric Y. Bois. (2006). Toxicokinetics of Inhaled Trichloroethylene and Tetrachloroethylene in Humans at 1 ppm: Empirical Results and Comparisons with Previous Studies. Toxicological Sciences. 95(1). 23–36. 35 indexed citations

20.

Micallef, Sandrine, et al.. (2005). L’analyse statistique bayésienne de données toxicocinétiques. HAL (Le Centre pour la Communication Scientifique Directe). 4(1). 21–34. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact